Market research
PIQ.AU Proteomics International Laboratories Limited
AU AUD Healthcare
Latest close
Loading market data…
Test a moving-average rule with historical data.
Market facts
- Market cap
- 23M
- P/E ratio
- Not available
- Analyst target
- 0.43
- Dividend yield
- Not available
- Beta
- -0.34
Profile
Company facts
- Exchange
- AU
- Currency
- AUD
- Sector
- Healthcare
- Industry
- Biotechnology
- ISIN
- AU000000PIQ0
- Market cap
- 23M
- P/E ratio
- Not available
- Analyst target
- 0.43
- Dividend yield
- Not available
- Beta
- -0.34
About
About Proteomics International Laboratories Limited
Proteomics International Laboratories Ltd operates as a medical technology company with a focus on the area of proteomics in Australia, New Zealand, the United States, Europe, and India. It provides PromarkerD, a blood test to predict chronic kidney disease in people with type 2 diabetes. The company's products under development include PromarkerEndo, which has completed clinical validation phase for endometriosis diagnosis; PromarkerEso, which has completed clinical validation trials for esophageal cancer diagnosis; and OxiDx (2-tag), which has completed clinical validation phase for oxidative stress treatment. The company also offers analytical services, such as biomarker discovery and validation, biosimilars/biologics characterisation, and pharmacokinetic testing. It has strategic collaboration with Harry Perkins Institute of Medical Research, Bioplatforms Australia, The University of Western Australia, Australian Research Council Training Centre, and the Australian Centre. Proteomics International Laboratories Ltd was founded in 2001 and is based in Nedlands, Australia.
Visit company websiteCommunity
Investor discussion
1 comment
Sign in to join the PIQ.AU discussion.
5 years, 5 months ago
Proteomics International Laboratories Limited is currently in a long term uptrend where the price is trading 7.5% above its 200 day moving average.
From a valuation standpoint, the stock is 61.4% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 99.3.
Proteomics International Laboratories Limited's total revenue sank by 35.5% to $602K since the same quarter in the previous year.
Its net income has dropped by 55.5% to $-2M since the same quarter in the previous year.
Finally, its free cash flow grew by 87.9% to $-190K since the same quarter in the previous year.
Based on the above factors, Proteomics International Laboratories Limited gets an overall score of 3/5.